As reported in Xconomy, Genentech's pertuzumab may be making a comeback - albeit somewhat limited - as a second antibody used in combination with trastuzumab (Herceptin) in some breast cancer patients. This is good news for an antibody that many thought dead and buried in 2005.
Pertuzumab targets a different portion of the HER2 receptor than Herceptin and has surprisingly, perhaps, been shown to offer greater clinical benefits to some patients when used in combination with Herceptin and standard chemotherapy. In a trial of 417 newly diagnosed patients, tumors disappered in 45.8 percent receiving the two antibodies as compared to 29 percent for those receiving Herceptin alone.
Phase III trials will now be conducted by Genentech and the possibility exists for pertuzumab to join trastuzumab as an enhanced treatment regime for HER2 positive breast cancer.
Posted by Bruce Lehr December 10th 2010.